Description
A host of new and old infectious diseases have emerged on the world stage, presenting familiar and novel challenges to public health officials. New strains of once controlled bacteria, new immunocomprimised patient populations, and new bioterror threats have spurred diagnostics companies to develop new tests and kits to meet the demand.
Kalorama has assembled the vital data developers and marketers need to understand the competitive and commercial landscape in three volumes:
Prion Disease; Viral Disease ; and Baterial & Protozoal Disease
Purchased separately, each volume costs $1995.00. A purchase of the entire series, however, entitles you to 20% off.
Table of Contents
Volume I: Prion Disease
Chapter One: Executive Summary
- Introductions
- Scope and Methodology
- Summary of Major Findings
Chapter Two: Prion Disease Primer
- Introduction
- Human Prion Diseases
- Variant Creutzfeldt-Jakob disease (vCJD)
- Gertsmann-Straussler-Scheinker (GSS) Syndrome
- Fatal Familial Insomnia (FFI)
- Kuru
- Animal Prion Disease
- Scrapie
- Bovine Spongiform Encephalopathy (BSE)
- Chronic Wasting Disease (CWD)
- Feline Spongiform Encephalopathy (FSE)
- Tranmissible Mink Encephalopathy (TME)
- Exotic Ungulate Encephalopathy
Chapter Three: The Technologies
- Prion Diagnostic Technology Definitions
- Polymerase Chain Reaction
- Synthetic Ligands
- Electrocardiogram (ECG)
- Immunoassays
- Nucleic Acid Hybridization
- Protein Misfolding Cyclic Amplifications (PMCA)
- Aptamer
- Capillary Electrophoresis and Chromatography
- Membrane-Based Preparative Electrophoresis
- Biomarkers
- Transgenic Mice
- Prion Diagnostic Competitors and Products
- Post-Mortem BSE Testing
- Post-Mortem Scrapie Prion Diagnostics
- Post-Mortem CWD Prion Diagnostics
- Ante-Mortem Prion Diagnostic Technology
- Ante-Mortem BSE Prion Diagnostic Technologies
- Ante-Mortem Scrapie Prion Diagnostics
- Ante-Mortem vCJD Prion
- Ante-Mortem CWD Prion Diagnostic Technologies
Chapter Four: The Markets
- Total TSE Post-Mortem Diagnostic Testing
- Post-Mortem BSE Cattle Testing
- Post-Mortem Scrapie Sheep (Ovine) Testing
- Post-Mortem Scrapie Caprine (Goat) Testing
- Post-Mortem CWD Testing
- Total Market
- CWD Testing in Wild and Captive Deer
- Ante-Mortem TSE Diagnostic Testing
- Emerging Markets
- Worldwide Sheep Genotyping
- Species Identification
- Prion Removal Techniques
Chapter Five: Conclusions and Strategic Implications
- First Conclusion
- Second Conclusion
- Third Conclusion
- Fourth Conclusion
Chapter Six: Company Profiles
- Abbott Laboratories
- Altegen, Inc.
- BIORAD
- Biotraces, Inc.
- Caprion Pharmaceuticals, Inc.
- Chronix Biomedical
- Gene Thera
- Gradipore Inc.
- Idexx Laboratories
- InPro Biotechnology
- InPro Biotechnology
- Microsens Biotechnologies
- Ortho-Clinical Diagnostics/Johnson & Johnson
- Prion Developmental Laboratories
- Prionics AG
- PrioSense Ltd.
- ProMetic Life Sciences
- Proteome Sciences plc
- Serono Pharmaceutical Research Institute
- TSEnse Diagnostics Ltd
- VMRD, Inc.
APPENDIX: Company Directory
List of Exhibits
Chapter Two: Prion Disease PrimeR
- Table 2-1: Number of Confirmed BSE Cases in Countries around the World
- Table 2-2: Number of CWD Affected Herds in North America by
- State or Province 2003
- Table 2-3: Summary of Prion Diseases, Hosts and Mechanism
Chapter Three: The Technologies
- Table 3-1: Number of Current Prion Diagnostic Competitors by Country
- Ante- and Post-Mortem 2003
- Table 3-2: Ante-Mortem & Post-Mortem Prion Diagnostic Companies
- Table 3-3: Ante- & Post-Mortem Prion Diagnostic Test by Technology and
- Number of Companies
- Table 3-4: Post-Mortem Prion Diagnostics by Companies and Technologies
- Table 3-5: Post-Mortem BSE Prion Diagnostic Test Technologies
- Table 3-6: Summary of Post-Mortem BSE Diagnostics on the Market or in Development
- Table 3-7: Post-Mortem Scrapie Prion Diagnostic Technologies
- Table 3-8: Summary of Post-Mortem Scrapie Diagnostics on the Market or in Development
- Table 3-9: Post-Mortem CWD Prion Diagnostic Technologies
- Table 3-10: Summary of Post-Mortem CWD Diagnostics on the Market or in Development
- Table 3-11: Ante-Mortem Prion Diagnostic Companies and Technologies
- Table 3-12: Ante-Mortem BSE Prion Diagnostic Technologies
- Table 3-13: Summary of Ante-Mortem BSE Diagnostics on the Market or in Development
- Table 3-14: Ante-Mortem Scrapie Prion Diagnostic Technologies
- Table 3-15: Summary of Ante-Mortem Scrapie Diagnostics on the Market or in Development
- Table 3-16: Ante-Mortem vCJD Prion Diagnostic Technologies
- Table 3-17: Summary of Ante-Mortem vCJD Diagnostics on the Market or in Development
- Table 3-18: Ante-Mortem CWD Prion Diagnostic Technologies
Chapter Four: The Markets
- Table 4-1: Worldwide TSE Post-Mortem Diagnostic Testing Revenue 2001-2008
- Table 4-2: Worldwide TSE Post-Mortem Diagnostic Testing Volume 2001-2008
- Table 4-3: Worldwide BSE Cattle Testing Revenue by Geographic Regions 2001-2008
- Table 4-4: Worldwide Post-Mortem BSE Cattle Testing Volume by Geographic Regions 2001-2008
- Figure 4-2: Distribution of Post-Mortem BSE Tests by Geography 2003
- Table 4-5: European Union & Acceding/EEA Countries Passive BSE Testing Revenues 2001, 2002, and First Four Months of 2003
- Table 4-6: European Union & Acceding/EEA Countries Passive BSE Testing Volume 2001, 2002, and First Four Months of 2003
- Figure 4-3: Total European Passive BSE Testing Revenue Distribution by Country 2002
- Table 4-7: European Union & Acceding/EEA Total Active BSE Screening Revenues by Country 2001-2003
- Table 4-8: European Union & Acceding/EEA Total Active BSE Screening Testing Volumes by Country 2001-2003
- Figure 4-4: Total Active European Passive BSE Testing Revenue Distribution by Country 2003
- Table 4-9: European Union & Acceding/EEA Healthy Slaughter Active BSE Screening Revenues by Country 2001-2003
- Table 4-10: European Union & Acceding/EEA Healthy Slaughter Active BSE Screening Testing Volume by Country 2001-2003
- Figure 4-5: Total European Healthy Slaughter Active BSE Screening Revenue Distribution by Country 2003
- Table 4-11: European Union & Acceding/EEA Other Active BSE Screening Revenue by Country 2001-2003
- Table 4-12: European Union & Acceding/EEA Other Active BSE Screening Testing Volume by Country 2001-2003
- Figure 4-6: Total European Other Active BSE Screening Distribution of Revenues by Country 2003
- Table 4-13: Worldwide Scrapie Sheep Testing Revenues by Geographic Region 2001-2008
- Table 4-14: Worldwide Scrapie Sheep Testing Volume by Geographic Region 2001-2008
- Table 4-15: Worldwide Scrapie Goat Post-Mortem Testing Revenue 2001-2008
- Table 4-16: Worldwide Scrapie Goat Post-Mortem Testing Volume 2001-2008
- Table 4-17: Worldwide CWD Post-Mortem Testing Revenues by Geographic Region 2001-2008
- Table 4-18: Worldwide CWD Post-Mortem Testing Volume by Geographic Region 2001-2008
- Table 4-19: CWD Post-Mortem Tests in the United States Revenues by Wild vs. Captive Deer 2001-2008
- Table 4-20: CWD Post-Mortem Tests in the United States Testing Volume by Wild vs. Captive Deer 2001-2008
- Table 4-21: CWD Post-Mortem Tests in Canada Revenues by Wild vs. Captive Deer 2001-2008
- Table 4-21: CWD Post-Mortem Tests in Canada Testing Volume by Wild vs. Captive Deer 2001-2008
- Table 4-25: Sheep Genotyping Testing Volume by Country
Volume II: Viral Disease. Kalorama Information
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Summary of Major Findings
CHAPTER TWO: EMERGING VIRAL INFECTIONS
- West Nile Virus
- Severe Acute Respiratory Syndrome (SARS)
- Hantaviruses
- Viral Hemorrhagic Fevers
- Ebola Virus
- Marburg Virus
- Crimean Congo (CCHF)
- Lassa Fever
- Yellow Fever
- Japanese Encephalitis (JE)
- West Nile Virus (WNV)
- Dengue (Group B Arbovirus)
CHAPTER THREE: THE MARKETS & TECHNOLOGIES
- West Nile Virus
- U.S. West Nile Virus Testing
- Canada WNV Testing
- Mexico WNV Testing
- HantaVirus
- Human Hantaviral Testing
- Rodent Hantavirus Testing
- Dengue
- SARS
- Japanese Encephalitis
CHAPTER FOUR: CONCLUSIONS AND STRATEGIC IMPLICATIONS
- First Conclusion
- Second Conclusion
- Third Conclusion
- Fourth Conclusion
- Fifth Conclusion
- Sixth Conclusion
CHAPTER FIVE: COMPANY PROFILES
- Abbott Laboratories
- AccuDX
- Arup Laboratories
- Bio Merieux
- Chiron
- Cypress Diagnostics
- Eragen Biosciences, Inc.
- Focus Technologies, Inc.
- GeneLabs Diagnostics Pte. Ltd.
- Gen-Probe
- Hennessy Research Associates
- InBIOS International
- LabCorp
- Medical Analysis Systems, Inc.
- MCC Medical and Clinical Consortium
- Mikrogen
- Ortho-Clinical Diagnostics/Johnson & Johnson
- PANBIO
- PROGEN
- Quest Diagnostics
- Roche/Roche Molecular Diagnostics
- Specialty Labs
- V.I. Technologies, Inc.
APPENDIX: COMPANY DIRECTORY
List of Exhibits
- Table 2-1: Number of SARS Cases & Deaths
- Table 2-2: Estimated number of Hanta Pulmonary Syndrome Cases in American Countries in 2003
- Table 2-3: Number of Ebola Cases by Country 1976-2003
- Table 2-4: Number of Suspect Yellow Fever Cases by Year and Country
- Table 2-5: Number of U.S. Human WNV Cases & Deaths
- Table 2-6: Number of Dengue Cases in the Americas by Region and Year
- Table 2-7: Number of Dengue Hemorrhagic Fever (DHF) Cases in the Americas by Region and Year
- Table 2-8: Number of Dengue Hemorrhagic Fever (DHF) Cases in Asia
- Table 2-9: Number of DHF Cases in Americas by Country 1981-2002
- Table 2-10: Dengue/DHF Outbreak Cases
- Table 3-1: Top Emerging Viral Infectious Disease Testing Revenue by Disease 2001-2008
- Table 3-2: Top Emerging Viral Infectious Disease Testing Volume by Disease 2001-2008
- Table 3-3: World West Nile Virus Testing Revenue by Region 2001-2008
- Table 3-4: World West Nile Virus Testing Volume by Region 2001-2008
- Table 3-5: U.S. West Nile Virus Testing Revenue by Segment 2001-2008
- Table 3-6: U.S. West Nile Virus Testing Volume by Category 2001-2008
- Table 3-7: U.S. Commercial West Nile Virus Testing* Revenue 2001-2008
- Table 3-8: U.S. Commercial West Nile Virus Testing* Volume 2001-2008
- Table 3-9: U.S. West Nile Virus Commercial Testing Market Share by Competitor 2002 and 2003
- Table 3-10: U.S. Human West Nile Virus Commercial Testing Volume by Competitor 2002 and 2003
- Table 3-11: U.S. Public Health West Nile Virus Testing Revenue by Species 2001-2008
- Table 3-12: U.S. Public Health West Nile Virus Testing Volume by Species 2001-2008
- Table 3-13: West Nile Virus Human Testing Volume by State 2001-2003
- Table 3-14: West Nile Virus Human Testing Revenue by State 2001-2003
- Table 3-15: U.S. West Nile Virus Avian Testing Volume by State, 2001-2003
- Table 3-16: U.S. WNV Avian Testing Revenue by State 2001-2003
- Table 3-17: U.S. WNV Mosquito Testing Volume by State 2001-1003
- Table 3-18: U.S. WNV Mosquito Testing Revenue by State 2001-2003
- Table 3-19: U.S West Nile Virus Chicken Testing Volume by State, 2001-2003
- Table 3-20: WNV Chicken Testing Revenue by State 2001-2003
- Table 3-21: U.S West Nile Virus Equine Testing Volume by State, 2001-2003
- Table 3-22: WNV Equine Testing Revenue
- Table 3-23: Health Canada WNV Testing Revenue by Species 2001-2008
- Table 3-24: Health Canada WNV Testing Volume by Species 2001-2008
- Table 3-25: Mexican Ministry of Health WNV Testing Revenue by Species 2001-2008
- Table 3-26: Mexican Ministry of Health WNV Testing Volume by Species 2001-2008
- Table 3-27: Hantavirus Testing Revenue by Region 2001-2008
- Table 3-28: HantaVirus Testing Volume by Region 2001-2008
- Table 3-29: Dengue Test Manufacturers
- Table 3-30: Sample of Dengue Test List Prices
- Table 3-31: Taiwan SARS Testing Volume by Technology 2002-2003
- Table 3-32: SARS Tests for Sale and in Development by Manufacturer
Volume III: Bacterial Disease
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Summary of Major Findings
CHAPTER TWO: BACTERIA AND PROTOZOA INFECTIOUS DISEASES
- Anthrax – Bacillus anthracis
- Brucella SPP
- Clostridium Botulinim
- Clostridium Perfringens
- Q Fever
- Staphyloccoccal Enterotoxin B
- Tuberculosis
- Vibrio cholerae
- Malaria
- Chagas Disease – Trypanosomiasis, T. cruzi
CHAPTER THREE: THE MARKETS & TECHNOLOGIES
- Introduction
- Environmental
- Clinical
- Clinical Anthrax Diagnostics
- Brucella
- Clostridium botulinim
- Clostridium perfringens
- Q Fever
- Staphylococcal Enterotoxin B
- Tuberculosis
- Vibrio cholerae
- Yersinia pestis
- Malaria
- Chagas Disease
CHAPTER FOUR: CONCLUSIONS AND STRATEGIC IMPLICATIONS
- First Conclusion
- Second Conclusion
- Third Conclusion
CHAPTER FIVE: COMPANY PROFILES
- Alexeter Technologies
- Becton, Dickinson, And Co.
- BioMerieux, Inc.
- Bio-Quant
- Diffchamb AB
- Gen-Probe
- Immuno-Biological Laboratories (IBL)
- Microgen Bioproducts
- New Horizon Diagnostics
- PANBIO
- r-Biopharm AG
- SA Scientific
- TechLab
- Teco Diagnostics
- TECRA International Pty Ltd.
- TetraCore Technologies
- V.I. Technologies, Inc.
APPENDIX A: COMPANY DIRECTORY
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: Summary of Emerging Infectious Disease Testing Market, 2001-2008
CHAPTER TWO: THE MARKETS AND TECHNOLOGIES
- Table 2-1: Number of TB Cases (All Forms) per WHO Region in 2000
- Table 2-2: Number of TB Cases (All Form) for 22 High-Burden Countries
- Table 2-3: Eastern Mediterranean Region Number of Notified Tuberculosis Cases, 1998-2002
- Table 2-4: Eastern Mediterranean Region Number of Notified Tuberculosis Cases by Country 2000-2002
- Table 2-5: Cholera Cases in the Americas 1991-2000
- Table 2-6: Cholera Outbreak Cases by Country 1996-2003
- Table 2-7: Confirmed Malaria Cases in 2001
- Table 2-8: WHO European Region Malaria Confirmed Cases 1991-2002
- Table 2-9: WHO European Region Malaria Confirmed Cases by Country, 2000-2002
- Table 2-10: Confirmed Malaria Cases in Top Nine European Regions & Countries 2000-2002
- Table 2-11: Eastern Mediterranean Region Severe Malaria Countries Estimate of Cases
- Table 2-12: WHO Roll Back Malaria Eastern Mediterranean Region Number of Confirmed Cases 2000-2002
- Table 2-13: Number of Laboratory Confirmed Malaria Cases Southeast Asia 1996-2001
CHAPTER THREE: CONCLUSIONS AND STRETEGIC IMPLICATIONS
- Table 3-1: Emerging Infectious Disease Testing Market Revenue by Testing Type 2001-2008
- Table 3-2: Environmental Bio-Threat Diagnostic Revenues by Method 2001-2008
- Table 3-3: Environmental Bio-Defense Lateral Flow Immunoassay Systems
- Table 3-4: Commercial HHA Anthrax Tests – Survey 1
- Table 3-5: Commercial HHA Anthrax Tests – Survey 2
- Table 3-7: Number of Counties, Parishes, or Independent Cities in the United States by State
- Table 3-8: Relative Limits of Detection of Selected Identification Technologies for Bacillus anthracis
- Table 3-9: Environmental Bio-Defense DNA Systems
- Table 3-10: Clinical Emerging Infectious Disease Testing Revenue by Disease 2001-2008
- Table 3-11: Antrax Test Manufacturers
- Table 3-12: Brucella Test Kits and Manufacturers by Geographic Region
- Table 3-13: SEB Antibody Tests
- Table 3-14: Tuberculosis Antibody Rapid Diagnostics
- Table 3-15: Tuberculosis Nucleic Acid Diagnostic Methods
- Table 3-16: Clinical Vibrio cholerae Diagnostics
- Table 3-17: Number of Laboratory Confirmed Malaria Cases by Region, 1999-2002
- Table 3-18: Number of Laboratory Confirmed Malaria Cases Southeast Asia, 1996-2001
- Table 3-19: Southeast Asia Malaria Estimate vs. Laboratory Confirmed Cases
- Table 3-20: Eastern Mediterranean Region Estimated Cases vs. Laboratory Confirmed Cases
- Table 3-21: Available Malaria Antigen & Antibody RDTs
- Table 3-22: Developing Malaria RDTs
- Table 3-23: Number of Latin America Blood Bank Samples Screened for T. cruzi 1994-2002
- Table 3-24: Percentage of Latin America Blood Bank Samples Screened for T. cruzi 1994-2002
- Table 3-25: Number of Blood Bank Donations in Latin America 1994-2000
- Table 3-26: Chagas Diagnostic Tests
- Table 3-27: Developing Chagas Diagnostics
